Alemtuzumab in T-cell malignancies

[1]  D. Catovsky,et al.  High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. , 2001, Blood.

[2]  J. Armitage.  Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor , 1998 .

[3]  G. Flandrin,et al.  Indolent course as a relatively frequent presentation in T‐prolymphocytic leukaemia , 1998, British journal of haematology.

[4]  G. Brittinger,et al.  CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Sigaux,et al.  Inactivation of the ATM gene in T-cell prolymphocytic leukemias. , 1998, Blood.

[6]  I. Vořechovský,et al.  ATM is usually rearranged in T-cell prolymphocytic leukaemia , 1998, Oncogene.

[7]  L. Ginaldi,et al.  Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. , 1998, Leukemia research.

[8]  R. Willemze,et al.  Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Dyer,et al.  In vivo‘Purging’ of residual disease in CLL with Campath‐1H , 1997, British journal of haematology.

[10]  M. Dyer,et al.  Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Catovsky,et al.  Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia , 1997, British journal of haematology.

[12]  K. Maclennan,et al.  The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Dexter,et al.  Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. , 1993, Blood.

[14]  R. Marcus,et al.  Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma , 1993, The Lancet.

[15]  D. Catovsky,et al.  Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. , 1991, Blood.

[16]  M. Dyer,et al.  Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. , 1990, Leukemia & lymphoma.

[17]  M. Dyer,et al.  Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. , 1989, Blood.

[18]  D. Catovsky,et al.  Prolymphocytic leukaemia of B and T cell type. , 1973, Lancet.